



# Patient Support Services

The single point of engagement for PYRUKYND<sup>®</sup>  
prescription and access support.

Visit [PYRUKYND.myAgios.com/hcp](https://PYRUKYND.myAgios.com/hcp) or call 1-800-951-3889.



Please see Important Safety Information throughout and full Prescribing Information for PYRUKYND in pocket.

FOR ADULT PATIENTS WITH PK DEFICIENCY

## myAgios® Patient Support Services: Single point of engagement for prescription and access support

Centralized enrollment for eligible patients, including prescription fulfillment, financial assistance, access, and adherence support



### ACCESS AND BENEFITS INVESTIGATION SERVICES

- Support with insurance coverage
- Administer patient assistance programs



### PRESCRIPTION FULFILLMENT THROUGH EXCLUSIVE SPECIALTY PHARMACY

- Commercial product dispensing
- Coordination of refills



### DEDICATED AND CLINICALLY EXPERIENCED PATIENT SUPPORT MANAGERS (PSMs) CAN OFFER:

- Single point of contact for HCPs and office staff to help patients access program offerings
- Educational resources and information about financial assistance and titration support

## INDICATION

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

## IMPORTANT SAFETY INFORMATION

**Acute Hemolysis:** Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

**Adverse Reactions:** Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities ( $\geq 10\%$ ) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.



## Prescribe PYRUKYND® in 3 steps

- 1** Fill out the PYRUKYND Enrollment Form at [PYRUKYND.myAgios.com/hcp/enrollment](https://PYRUKYND.myAgios.com/hcp/enrollment).
- 2** Submit the form to myAgios online or call a PSM with any questions at **1-800-951-3889**.
- 3** A dedicated myAgios PSM will reach out to office staff and patients directly to provide support throughout the treatment process.

# Financial assistance options and coverage support

myAgiOS can connect patients to financial assistance and coverage support programs to help with access to PYRUKYND, including information about:



## THE PYRUKYND COPAY PROGRAM

- This program lowers costs for eligible patients to \$0 per prescription if their copay exceeds that amount
- To learn more about patient eligibility, call myAgiOS Patient Support Services at **1-800-951-3889**
- Patients participating in government healthcare insurance are not eligible



## COVERAGE INTERRUPTION

- This program is for eligible commercially insured patients who have filled at least one previous prescription of PYRUKYND and who experience a temporary loss or change in coverage
- Eligible patients experiencing an interruption in coverage can receive a free 28-day prescription (with up to two refills)
- Patients participating in government healthcare insurance are not eligible



## THE PATIENT ASSISTANCE PROGRAM (PAP)

- May offer free prescriptions to eligible uninsured and underinsured patients
- If a patient is uninsured or underinsured, contact their PSM to discuss the options for this patient's specific case
- PAP prescriptions will be reviewed and filled by myAgiOS if approved. If approved, patients must reapply annually and continue to meet income and program eligibility requirements each calendar year
- To learn more about patient eligibility requirements, start by calling myAgiOS at **1-800-951-3889**

Other forms of assistance may be available, including assistance from independent foundations for patients with government insurance or insufficient commercial insurance. Eligibility is determined by the individual foundation. Agios is not affiliated with these organizations.

## IMPORTANT SAFETY INFORMATION (cont.)

### Drug Interactions:

- Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
- Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
- Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
- Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
- UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
- P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Please see additional Important Safety Information throughout and full Prescribing Information for PYRUKYND in pocket.



# Agios' experienced and dedicated Patient Support Managers can offer assistance for patients



## myAgios® Patient Support Managers:

- Have over 20 years of collective experience with rare diseases
- Tailor the support experience for patients and their caregivers based upon their unique needs in living with PK deficiency
- Can direct patients to PYRUKYND® and PK deficiency educational resources, including community connections
- Help patients navigate financial assistance questions and eligibility criteria
- Can be a supportive resource and provide adherence support through
  - Social support via patient webinars with other PK deficiency patients and caregivers
  - Regular phone calls (cadence is approximately monthly)
  - Email communications

When a patient is prescribed PYRUKYND and the enrollment form is received by myAgios, the process for support can begin. HIPAA consent must be obtained to complete enrollment into the myAgios program.



Connect patients with a dedicated Patient Support Manager to ask questions.

Call **1-800-951-3889**, Mon-Fri, 8 AM to 6 PM ET or visit [PYRUKYND.myAgios.com/hcp](https://www.pyrukynd.com/hcp) to learn more.

This program is not intended as medical advice and patients should consult their healthcare team with questions related to their treatment.

## IMPORTANT SAFETY INFORMATION (cont.)

**Hepatic Impairment:** Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see additional Important Safety Information throughout and full Prescribing Information for PYRUKYND in pocket.



myAgios is a registered trademark of Agios Pharmaceuticals, Inc.  
©2023 Agios Pharmaceuticals, Inc. All rights reserved. PYR-US-0013v2 1/23

